1 Energy-Efficient Downlink for Non-Orthogonal Multiple Access with SWIPT under Constrained Throughput

2 Field optimization of the sex pheromone of Stenoma catenifer (Lepidoptera: Elachistidae): evaluation of lure types, trap height, male flight distances, and number of traps needed per avocado orchard for detection.

3 Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma: International Multicenter Cohort Study.

4 Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

5 Risk stratification and prognostication of renal cell carcinoma.

6 Biological Response to Carbon-Family Nanomaterials: Interactions at the Nano-Bio Interface.

7 Doneness preferences, meat and meat-derived heterocyclic amines intake, and N-acetyltransferase 2 polymorphisms: association with colorectal adenoma in Japanese Brazilians.

8 Acute Renal Transplant Failure Secondary to an Obstructing Ileal Conduit Adenocarcinoma: Case Report and Literature Review.

9 Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy.

10 Colorimetric and Fluorogenic Chemosensors for Mercury Ion Based on Nanomaterials

11 YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage

12 Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy.

13 Interventions to Prevent Nonmelanoma Skin Cancers in Recipients of a Solid Organ Transplant: Systematic Review of Randomized Controlled Trials.

14 Hybrid Organometallic-Inorganic Nanomaterial: Acetyl Ferrocene Schiff base Immobilized on Silica Coated Magnetite Nanoparticles

15 Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

16 NoMap: Speeding-up javascript using hardware transactional memory

17 Immunohistochemical localization of nephrocalcin, a kidney-specific glycoprotein, to renal cell carcinoma.

18 Synthetic Multienzyme Complexes, Catalytic Nanomachineries for Cascade Biosynthesis In Vivo.

19 Targeting hepatocellular carcinoma: Synthesis of new pyrazole-based derivatives, biological evaluation, DNA binding, and molecular modeling studies

20 İlhanlı Hâkimiyeti Altında Anadolu’da Siyasetin Temel Dinamiği: Göçebe Moğol-Türkmen Çatışması <br> The Basic Dynamic Of Politics In Anatolia Under The Ilkhanid Rule: The Struggle Of Nomad Turcomans And Mongols

21 Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study.

22 High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules.

23 IslandCafe: Compositional Anomaly and Feature Enrichment Assessment for Delineation of Genomic Islands.

24 Plasmonic Nanomaterial-Based Optical Biosensing Platforms for Virus Detection

25 Facebook Intervention for Young-Onset Melanoma Patients and Their Family Members: Pilot and Feasibility Study

26 Social Media as a Platform for Information and Support for Melanoma Patients: Analysis of Melanoma Facebook Groups and Pages

27 ANOMALOUS ACTIVITY DETECTION FROM DAILY SOCIAL MEDIA USER MOBILITY DATA

28 Ambovex® as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial

29 Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

30 Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma

31 Intermediate stage hepatocellular carcinoma: a summary review

32 Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

33 Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma

34 Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

35 Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

36 Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

37 Weighing the benefits of hepatocellular carcinoma surveillance against potential harms

38 Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions

39 Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

40 Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist

41 Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

42 Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

43 Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

44 Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance

45 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

46 Editorial: charting the future of hepatocellular carcinoma publications

47 Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt

48 Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma

49 Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

50 Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

51 Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

52 Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma

53 Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

54 Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

55 Hepatocellular carcinoma: early-stage management challenges

56 Screening for hepatocellular carcinoma: patient selection and perspectives

57 Open-label phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

58 Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

59 A single institution report of 19 hepatocellular carcinoma patients with bile duct tumor thrombus

60 Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge

61 Pediatric hepatocellular carcinoma: challenges and solutions

62 Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients

63 Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration

64 Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

65 GPC-3 in hepatocellular carcinoma: current perspectives

66 Minimally invasive image-guided therapies for hepatocellular carcinoma

67 Hepatocellular carcinoma: a review

68 Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary

69 Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

70 Transarterial radioembolization for hepatocellular carcinoma: a review

71 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

72 Hepatocellular carcinoma in elderly patients: challenges and solutions

73 Fibrolamellar hepatocellular carcinoma: current clinical perspectives

74 Role of endoscopic ultrasound in diagnosis and management of hepatocellular carcinoma

75 Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

76 Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

77 Whither α-FP in the diagnosis of hepatocellular carcinoma?

78 The androgen receptor as an emerging target in hepatocellular carcinoma

79 Emerging role of Hpo signaling and YAP in hepatocellular carcinoma

80 Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy

81 Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields

82 Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

83 c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma

84 A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma

85 Emerging role of Toll-like receptor 4 in hepatocellular carcinoma

86 Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors

87 Welcome to Journal of Hepatocellular Carcinoma

88 Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy

89 Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

90 Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments

91 Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models

92 Radiological diagnosis of hepatocellular carcinoma

93 Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma

94 Hepatocellular carcinoma: epidemiology and risk factors

95 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

96 Clinical utility of imaging for evaluation of hepatocellular carcinoma

97 Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

98 New insights on the role of epigenetic alterations in hepatocellular carcinoma

99 Potential immunotherapeutic role of interleukin-2 and interleukin-12 combination in patients with hepatocellular carcinoma

100 Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma

101 Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma

Keyword Connections

Journals

Research Groups

Bibliographies